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Purpose
The purpose of this study was to investigate the effect of hospital case volume on clinical
outcomes in patients with nasopharyngeal carcinoma (NPC).   
Materials and Methods
Data on 1,073 patients with cT1-4N0-3M0 NPC were collected from a multi-institutional ret-
rospective database (KROG 11-06). All patients received definitive radiotherapy (RT) either
with three-dimensional-conformal RT (3D-CRT) (n=576) or intensity-modulated RT (IMRT)
(n=497). The patients were divided into two groups treated at high volume institution (HVI)
(n=750) and low volume institution (LVI) (n=323), defined as patient volume  10 (median,
13; range, 10 to 18) and < 10 patients per year (median, 3; range, 2 to 6), respectively. End-
points were overall survival (OS) and loco-regional progression-free survival (LRPFS).
Results
At a median follow-up of 56.7 months, the outcomes were significantly better in those
treated at HVI than at LVI. For the 614 patients of propensity score-matched cohort, 5-year
OS and LRPFS were consistently higher in the HVI group than in the LVI group (OS: 78.4%
vs. 62.7%, p < 0.001; LRPFS: 86.2% vs. 65.8%, p < 0.001, respectively). According to RT
modality, significant difference in 5-year OS was observed in patients receiving 3D-CRT
(78.7% for HVI vs. 58.9% for LVI, p < 0.001) and not in those receiving IMRT (77.3% for HVI
vs. 75.5% for LVI, p=0.170). 
Conclusion
A significant relationship was observed between HVI and LVI for the clinical outcomes of
patients with NPC. However, the difference in outcome becomes insignificant in the IMRT
era, probably due to the standardization of practice by education.
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Introduction
Surgeon expertise has a great impact on the treatment out-
come of cancer surgery, and on surgical morbidity [1-3]; the
expertise of the radiation oncologist presumably has the
same impact on outcome and morbidity in radiotherapy
(RT), but this has not been well documented. To practice
“state of the art” RT, a radiation oncologist should have
knowledge of the natural history of the disease, proper 
incorporation of multimodal images, and cross-sectional
anatomy; they should also be able to precisely delineate tar-
get volume, develop an optimal treatment plan with an 
adequate dose to the target volume, avoid critical organs,
and accurately deliver the daily treatment. RT with insuffi-
cient target coverage and an excessive dose to critical organs
can result in lower loco-regional control, a higher incidence
of late toxicity, and poorer survival outcome. Therefore, sub-
stantial knowledge and experience are required to provide
high quality RT. Differences in the knowledge and experi-
ence among providers can make a difference in the outcome
of RT [4-6] in patients with head and neck cancer, particu-
larly in the era of three-dimensional-conformal RT (3D-CRT)
or intensity-modulated RT (IMRT). However, there is sub-
stantial heterogeneity in target volume delineation and clin-
ical practice among radiation oncologists [5], depending on
their experience and knowledge. Therefore, we postulated
that the experience of a radiation oncologist, as indexed by
hospital case volume (HCV), might have an impact on treat-
ment outcome in patients with nasopharyngeal cancer
(NPC).
NPC arises from anatomically challenging region, but is
highly radio-curable disease, which makes RT with or with-
out chemotherapy the mainstay of treatment [7]. Thus, NPC
might be a good candidate disease to evaluate the impact of
radiation oncologists’ experience on treatment outcome. We
retrospectively investigated the effect of HCV on overall sur-
vival (OS) and loco-regional progression-free survival
(LRPFS) in patients with NPC enrolled in a retrospective
multi-center trial (Korean Radiation Oncology Group
[KROG] 11-06).
Materials and Methods
1. Data source and study population
We collected the data of patients with cT1-4N0-3M0 NPC
from a NPC study database (KROG 11-06). KROG 11-06 was
a retrospective multi-center trial which included 14 institu-
tions that reviewed the NPC pattern of care and treatment
outcomes in patients with primary NPC treated from Sep-
tember 1988 to October 2011 [8]. The inclusion criteria were
histologically confirmed NPC, cT1-4N0-3M0 disease accord-
ing to the seventh editions of Union for International Cancer
Control/American Joint Committee on Cancer (UICC/AJCC)
staging classification. At the time of data collection, patients
who had no baseline clinical information or had never com-
pleted RT were excluded from data collection. All patients
on the data base were included for this analysis. Computa-
tional tomography was routinely done in all institutions for
staging assessment. Magnetic resonance image (MRI) or
positron emission tomography (PET) was also used for stag-
ing in some institutions. 
After excluding patients treated with two-dimensional
(2D) RT, 1,073 patients were analyzed. All patients received
definitive RT either with 3D-CRT (n=576) or IMRT (n=497).
The mean (±standard deviation [SD]) total 3D-CRT dose was
67.99±2.64 Gy in 38.0±2.8 fractions with a median fraction
size of 1.80 Gy (range, 1.50 to 2.40 Gy). The mean±SD total
dose for IMRT was 69.49±3.18 Gy in 31.8±3.4 fractions with
a median fraction size of 2.25 Gy (range, 1.8 to 3.0 Gy), 
reflecting use of the concomitant boost technique.  
2. Primary endpoint and covariates
To investigate associations between treatment outcome
and institutional volume, the institutions were divided into
high volume institutions (HVI) and low volume institutions
(LVI) (S1 Table). The number of patients treated per year was
calculated by dividing the total number of patients by the
total period over which the patients were treated at each 
institution and it ranged from 2 to 18. HVI was defined as
patient volume  10 patients per year (median, 13; range, 10
to 18) and LVI as patient volume < 10 patients per year 
(median, 3; range, 2 to 6). Ten patients per year was chosen
as cut-point because there was the largest gap between the
two consecutive values of 10 and 6. A total of 750 patients
were treated at 4 HVIs and 323 were treated at 10 LVIs.
The endpoints of this study were OS and LRPFS, which
were defined as the time from the start of RT to the time of
death from any cause (OS), and persistence or recurrence in
the nasopharynx or neck (LRPFS). Patients who had lost to
follow-up were censored at the time of their last follow-up.
The variables analyzed were age, Eastern Cooperative 
Oncology Group (ECOG) performance status (PS), World
Health Organization (WHO) histologic type, TN category,
stage grouping, the utilization of MRI or PET for staging,
concurrent chemo-radiotherapy (CCRT; yes or no), RT
modality (3D or IMRT), and institutional case volume (HVI
or LVI).
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3. Statistical analysis
Baseline characteristics of the patients treated at HVI and
LVI were compared with the t test for continuous variables
and the chi-square test for categorical variables. The Kaplan-
Meier method was used to assess event-time distributions
and the log-rank test was used to compare the event-time
distributions between the two groups. In both the univariate
and multivariate analyses, a p < 0.05 was considered signif-
icant. A Cox proportional hazard model was used with step-
wise backward linear regression, where only variables whose
p-values were > 0.10 were removed and used in multivariate
analyses. Since there was significant imbalance in patient
characteristics between HVI and LVI, propensity score
matching analysis was done to reduce bias due to confound-
ing variables. The propensity score was estimated using a 
logistic regression model including variables of age, ECOG
PS, WHO histologic classification, TN category, stage group,
Table 1.  Patient characteristics before propensity score matching
Characteristic HVI LVI Total p-value(n=750) (n=323) (n=1,073)
Age, median (range, yr) 49.8 (16-86) 52.8 (18-77) 50.5 (16-86) < 0.001
Sex
Female 197 (26.3) 103 (31.9) 300 (28.0) 0.060
Male 553 (73.7) 220 (68.1) 773 (72.0)
ECOG PS
0-1 717 (95.6) 308 (95.4) 1,025 (95.5) 0.859
2 33 (4.4) 15 (4.6) 48 (4.5)
WHO histologic classification
I 111 (14.8) 51 (15.8) 162 (15.1) < 0.001
II 258 (34.4) 65 (20.1) 323 (30.1)
III 343 (45.7) 191 (59.1) 534 (49.8)
Unknown 38 (5.1) 16 (5.0) 54 (5.0)
T category
1-2 435 (58.0) 170 (52.6) 605 (56.4) 0.104
3-4 315 (42.0) 153 (47.4) 468 (43.6)
N category
0-1 315 (42.0) 155 (48.0) 470 (43.8) 0.070
2-3 435 (58.0) 168 (52.0) 603 (56.2)
Stage group
I-II 179 (23.9) 89 (27.6) 268 (25.0) 0.201
III-IV 571 (76.1) 234 (72.4) 805 (75.0)
MRI
Not done 240 (32.2) 220 (69.4) 460 (43.3)
Done 506 (67.8) 97 (30.6) 603 (56.7) < 0.001
PET
Not done 410 (55.0) 250 (79.1) 660 (62.1)
Done 336 (45.0) 66 (20.9) 402 (37.9) < 0.001
Radiotherapy
3D-CRT 359 (47.9) 217 (67.2) 576 (53.7) < 0.001
IMRT 391 (52.1) 106 (32.8) 497 (46.3)
CCRT
No 183 (24.4) 77 (23.8) 260 (24.2) 0.844
Yes 567 (75.6) 246 (76.2) 813 (75.8)
Values are presented as number (%). HVI, high volume institutions; LVI, low volume institutions; ECOG PS, Eastern Coop-
erative Oncology Group performance status; WHO, World Health Organization; MRI, magnetic resonance image; PET,
positron emission tomography; 3D-CRT, three-dimensional-conformal radiotherapy; IMRT, intensity-modulated radiother-
apy; CCRT, concurrent chemo-radiotherapy.
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Fig. 1.  Kaplan-Meier survival curves of overall survival (OS) (A) and loco-regional progression-free survival (LRPFS) (B)
for both groups in entire cohort and propensity score-matched cohort. The OS (C) and LRPFS (D) were significantly higher
in high volume institutions (HVI) than in low volume institutions (LVI) for the cohort before and after propensity score
matching.
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RT modality (3D or IMRT) and concurrent chemotherapy
(yes or no). 
4. Ethical statement
KROG 11-06 was approved by the institutional review
boards of each participating hospital and performed in accor-
dance with the principles of the Declaration of Helsinki. The
informed consent was waived.
Results
1. Patient characteristics and survival of the cohort before
propensity score matching
The patient and treatment characteristics stratified by HVI
and LVI are summarized in Table 1. The median follow-up
time was 56.7 months (range, 0 to 244 months). Median age
Characteristic No. of 
OS LRPFS
patients HR 95% CI p-value HR 95% CI p-value
Age (yr)
< 50 492 1.00 - < 0.001 1.00 - 0.123
 50 581 1.88 1.47-2.40 1.24 0.94-1.64
ECOG PS
0-1 1,025 1.00 - 0.001 1.00 - 0.044
2 48 2.16 1.46-3.21 1.73 1.02-2.93
WHO histologic classification
I 162 1.00 - < 0.001 1.00 - 0.002
II 323 0.57 0.41-0.79 0.54 0.37-0.79
III 534 0.81 0.47-1.40 0.52 0.37-0.74
Unknown 54 - - 0.82 0.45-1.52
T category
1-2 605 1.00 - < 0.001 1.00 - < 0.001
3-4 468 1.72 1.29-2.30 1.78 1.35-2.34
N category
0-1 470 1.00 - 0.015 1.00 - 0.304
2-3 603 1.46 1.08-1.97 1.21 0.84-1.75
Stage group
I-II 268 1.00 - 0.060 1.00 - 0.658
III-IV 805 1.61 0.98-2.63 1.13 0.66-1.95
MRI
Not done 460 1.00 - 0.267 1.00 - 0.840
Done 603 1.17 0.89-1.55 1.04 0.74-1.45
PET
Not done 660 1.00 - 0.111 1.00 - 0.307
Done 402 0.79 0.59-1.06 0.84 0.60-1.18
Radiotherapy
3D-CRT 576 1.00 - 0.218 1.00 - 0.959
IMRT 497 0.85 0.66-1.10 0.99 0.74-1.33
HCV
HVI 750 1.00 - < 0.001 1.00 - < 0.001
LVI 323 2.03 1.60-2.57 2.14 1.63-2.80
Table 2. Multivariate analysis of the prognostic variables for predicting OS and LRPFS
OS, overall survival; LRPFS, loco-regional progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG PS,
Eastern Cooperative Oncology Group performance status; WHO, World Health Organization; MRI, magnetic resonance
image; PET, positron emission tomography; 3D-CRT, three-dimensional-conformal radiotherapy; IMRT, intensity-modulated
radiotherapy; HCV, hospital case volume; HVI, high volume institutions; LVI, low volume institutions.
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was older in patients treated at HVI versus LVI. A lower pro-
portion of patients treated at HVI had WHO histologic grade
III tumors (45.7% vs. 59.1%, p < 0.001). MRI and PET were
more frequently used for staging in patients treated at HVI
than at LVI (MRI, 67.8% vs. 30.6%, p < 0.001; PET, 45.0% vs.
20.9%, p < 0.001, respectively). HVI were more likely to treat
patients with IMRT than 3D-CRT (52.1% vs. 32.8%, p <
0.001). A total of 304 patients died. Fig. 1 shows the Kaplan-
Meier survival curves for both groups. The OS was signifi-
cantly higher in HVI than LVI for the cohort before
propensity score matching (5-year, 78.1% vs. 62.5%; 10-year,
69.7% vs. 47.9%; p < 0.001). HVI was associated with higher
OS compared with LVI in the multivariate Cox regression
model (hazard ratio [HR], 0.48; 95% confidence interval [CI],
0.38 to 0.61; p < 0.001) (Table 2). Other variables significantly
associated with OS were age, PS, WHO histologic classifica-
tion, and TN category.
HVI was associated with significantly longer LRPFS com-
pared to that of LVI (5-year, 81.8% vs. 66.0%; 10-year, 77.5%
vs. 63.3%; p < 0.001) (Fig. 1). This survival benefit at HVI was
also seen in the multivariate analysis (HR, 0.45; 95% CI, 0.34
to 0.59; p < 0.001) (Table 2). 
2. Patient characteristics and survival of the cohort after
propensity score matching
A propensity score matching analysis was performed to
reduce bias due to confounding variables. Of the patients
treated at LVI, 307 were matched with 307 patients treated
at HVI. Table 3 shows the patients characteristics for the
propensity score-matched cohort. Variables including age,
WHO histologic classification, and RT modality (3D-CRT vs.
Table 3.  Patient characteristics after propensity score matching
Characteristic HVI LVI Total p-value(n=307) (n=307) (n=614)
Age, median  (range, yr) 52 (16-76) 53 (18-77) 53 (16-77) 0.199
Sex
Female 78 (25.4) 100 (32.6) 178 (29.0) 0.062
Male 229 (74.6) 207 (67.4) 436 (71.0)
ECOG PS
0-1 296 (96.4) 292 (95.1) 588 (95.8) 0.549
2 11 (3.6) 15 (4.9) 26 (4.2)
WHO histologic classification
I 39 (12.7) 48 (15.6) 87 (14.2) 0.785
II 68 (22.1) 65 (21.2) 133 (21.7)
III 187 (60.9) 180 (58.6) 367 (59.8)
Unknown 13 (4.2) 14 (4.6) 27 (4.4)
T category
1-2 160 (52.1) 170 (55.4) 330 (53.7) 0.466
3-4 147 (47.9) 137 (44.6) 284 (46.3)
N category
0-1 134 (43.6) 142 (46.3) 276 (45.0) 0.570
2-3 173 (56.4) 165 (53.7) 338 (55.0)
Stage group
I-II 74 (24.1) 89 (29.0) 163 (26.5) 0.201
III-IV 233 (75.9) 218 (71.0) 451 (73.5)
Radiotherapy
3D-CRT 204 (66.4) 201 (65.5) 405 (66.0) 0.865
IMRT 103 (33.6) 106 (34.5) 209 (34.0)
CCRT
No 73 (23.8) 75 (24.4) 148 (24.1) 0.925
Yes 234 (76.2) 232 (75.6) 466 (75.9)
Values are presented as number (%). HVI, high volume institutions; LVI, low volume institutions; ECOG PS, Eastern Coop-
erative Oncology Group performance status; WHO, World Health Organization; 3D-CRT, three-dimensional-conformal 
radiotherapy; IMRT, intensity-modulated radiotherapy; CCRT, concurrent chemo-radiotherapy.
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IMRT) were well-balanced between the two groups after
propensity score matching. 
A total of 196 patients died at a median follow-up of 55
months. As shown in the Kaplan-Meier survival curves for
both groups in the propensity score-matched cohort (Fig. 1),
OS was significantly higher in HVI than LVI (5-year, 78.4%
vs. 62.7%; 10-year, 71.6% vs. 47.0%; p < 0.001, respectively).
The multivariate Cox regression revealed that HVI was 
associated with higher OS than LVI, with an estimated HR
of 0.43 (95% CI, 0.32 to 0.57; p < 0.001). Other variables asso-
ciated with OS in multivariate analysis were age, PS, WHO
histologic classification, and stage group (Table 4).
As shown in Fig. 1, LRPFS was significantly higher in HVI
than in LVI (5-year, 86.2% vs. 65.8%; 10-year, 80.9% vs. 63.0%;
p < 0.001). The LRPFS difference remained significant in
favor of patients treated at HVI in the multivariate analysis
(HR, 0.34; 95% CI, 0.23 to 0.49; p < 0.001). Other variable 
associated with LRPFS was T category (Table 4).
To determine the impact of RT modality, the propensity
score-matched cohort was divided into 3D-CRT and IMRT
groups. Significant differences in OS (5-year OS, 78.7% for
HVI vs. 58.9% for LVI; p < 0.001) and LRPFS (5-year LRPFS,
83.6% for HVI vs. 67.1% for LVI; p < 0.001) were observed in
the 3D-CRT group (Fig. 2). No differences in OS (5-year OS,
77.3% for HVI vs. 75.5% for LVI; p=0.170) or LRPFS (5-year
LRPFS, 84.3% for HVI vs. 84.1% for LVI; p=0.692) were 
observed in the IMRT group (Fig. 2). 
Characteristic No. of 
OS LRPFS
patients HR 95% CI p-value HR 95% CI p-value
Age (yr)
< 50 241 1.00 - < 0.001 1.00 - 0.060
 50 373 1.85 1.31-2.59 1.44 0.99-2.11
ECOG PS
0-1 588 1.00 - 0.007 1.00 - 0.117
2 26 2.10 1.22-3.61 1.78 0.87-3.66
WHO histologic classification
I 87 1.00 - 0.036 1.00 - 0.105
II 133 0.51 0.30-0.85 0.61 0.32-1.15
III 367 0.51 0.33-0.79 0.53 0.30-0.91
Unknown 27 0.63 0.29-1.35 0.86 0.37-2.00
T category
1-2 330 1.00 - 0.088 1.00 - < 0.001
3-4 284 1.36 0.96-1.95 1.99 1.38-2.87
N category
0-1 276 1.00 - 0.257 1.00 - 0.412
2-3 338 1.28 0.84-1.95 1.24 0.74-2.08
Stage group
I-II 163 1.00 - < 0.001 1.00 - 0.716
III-IV 451 2.77 1.65-4.65 1.15 0.54-2.43
Radiotherapy
3D-CRT 409 1.00 - 0.292 1.00 - 0.777
IMRT 209 0.82 0.57-1.19 0.94 0.62-1.43
HCV
HVI 307 1.00 - < 0.001 1.00 - < 0.001
LVI 307 2.36 1.72-3.25 2.99 2.03-4.42
Table 4. Multivariate analysis of the prognostic variables for predicting OS and LRPFS in the propensity score-matched 
cohort
OS, overall survival; LRPFS, loco-regional progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG PS,
Eastern Cooperative Oncology Group performance status; WHO, World Health Organization; 3D-CRT, three-dimensional-
conformal radiotherapy; IMRT, intensity-modulated radiotherapy; HCV, hospital case volume; HVI, high volume institu-
tions; LVI, low volume institutions.
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Fig. 2.  Kaplan-Meier survival curves of overall survival (OS) (A, C) and loco-regional progression-free survival (LRPFS) 
(B, D) for both groups in the subgroups of patients treated with three-dimensional-radiotherapy (3D-CRT) and intensity-
modulated radiotherapy (IMRT) in the propensity score-matched cohort. Significant differences in OS (p < 0.001) and LRPFS
(p < 0.001) were observed in the 3D-CRT group and not in the IMRT group.
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3. Toxicity
Acute grade  3 toxicities occurred less frequently in 
patients treated at HVI than those treated at LVI: hemato-
logic toxicity (3.1% vs. 19.2%, p < 0.001), mucositis (18.4% vs.
22.0%, p=0.003), and xerostomia (0.9% vs. 9.0%, p < 0.001).
Xerostomia  grade 2 at 2 years after treatment was more fre-
quently reported in patients treated at HVI than those treated
at LVI (13.0% vs. 7.4%, p=0.046). However, this difference was
not statistically significant in the propensity score-matched
cohort (12.5% vs. 8.0%, p=0.126, respectively) (Table 5). Other
late toxicities were reported in less than 3% of patients and
the incidences were comparable between HVI and LVI. Two
patients (0.3%) in HVI and eight patients (2.5%) in LVI died
of treatment related toxicity. 
Discussion
This study demonstrated a significant relationship 
between institutional volume and long-term outcomes of
NPC. A higher institutional volume was associated with
higher OS (HR, 2.09; 95% CI, 1.65 to 2.64; p < 0.001) and
LRPFS (HR, 2.22; 95% CI, 1.69 to 2.91; p < 0.001). This differ-
ence remained significant after adjusting for covariates in the
multivariate and propensity score matching analyses. These
findings are consistent with other studies evaluating the vol-
ume effect in patients treated with definitive RT at diverse
cancer sites, including high-risk prostate cancer, locally-
advanced lung cancer, and NPC [9-12].
Wuthrick et al. [13] performed a secondary analysis of the
RTOG 0129 stage III-IV head and neck cancer RT trial, in
which all patients received definitive RT with IMRT, and 
reported a greater risk of death in patients treated at histor-
HVI (n=307) LVI (n=307) Total (n=714) p-value
Acute toxicity
Hematologic
Grade 3 8 (2.6) 50 (16.3) 58 (9.5) < 0.001a)
Grade 4 0 ( 11 (3.6) 11 (1.8)
Grade 5 0 ( 1 (0.3) 1 (0.2)
Mucositis
Grade 3 34 (11.1) 60 (20.0) 94 (15.3) 0.001a)
Grade 4 0 ( 5 (1.6) 5 (0.8)
Xerostomia
Grade 3 2 (0.7) 27 (8.8) 29 (4.7) < 0.001b)
Skin
Grade 3 12 (3.9) 10 (3.3) 22 (3.6) 0.664b)
Late toxicity  grade 3
Skin telangiectasia/Neck fibrosis 5 (1.6) 5 (1.6) 10 (1.6) > 0.999b)
Mucositis 11 (3.6) 8 (2.6) 19 (3.1) 0.484b)
Bone necrosis 2 (0.7) 1 (0.3) 3 (0.5) > 0.999a)
Carotid artery stenosis/Rupture 2 (0.7) 1 (0.3) 3 (0.5) > 0.999a)
Brain necrosis/Myelopathy 4 (1.3) 4 (1.3) 8 (1.3) > 0.999a)
CN palsy/Brachial plexopathy 4 (1.3) 4 (1.3) 8 (1.3) > 0.999a)
Hearing difficulty/Labyrinthitis 2 (0.7) 4 (1.3) 6 (1.0) 0.686a)
Dysphagia 3 (1.0) 1 (0.3) 4 (0.7) 0.624a)
Xerostomia (at 2 years F/U)c)
Grade 2 30 (11.7) 17 (8.0) 47 (9.9) 0.126a)
Grade 3 2 (0.8) 0 ( 2 (0.4)
Treatment related death 2 (0.7) 8 (2.6) 10 (1.6) 0.056b)
Table 5. Acute and late toxicities according to the HCV in the propensity score-matched cohort
Values are presented as number (%). HCV, hospital case volume; HVI, high volume institutions; LVI, low volume institutions;
CN, cranial nerve; F/U, follow-up. a)By Fisher exact test, b)By chi square test, c)Xerostomia at 2 years F/U were assessed in a
total of 474 patients (256 in HVI and 218 in LVI).
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ically low-volume accrual centers (HR, 1.91; 95% CI, 1.37 to
2.65). Boero et al. [14] published the results of a retrospective
analysis of 6,212 patients with head and neck cancer using
the SEER-Medicare database. They found a significant rela-
tionship between provider volume and survival only for 
patients receiving IMRT (HR, 0.79; 95% CI, 0.67 to 0.94), but
not for patients receiving conventional non-IMRT [14]. How-
ever, it is difficult to compare these results with ours because
the two studies included only a small proportion of NPC
cases (0%-2%) and the latter study also enrolled 35% patients
who underwent surgery prior to RT. Only one other study
included patients with NPC; Lee et al. [12] retrospectively
analyzed the Taiwan National Health Insurance Research
Database data of 1,225 patents treated between 1998 and
2000. They found that patients treated by high-volume physi-
cians had a 14% relative improvement in adjusted 10-year
survival rate (high-volume vs. low/medium-volume physi-
cians, 75% vs. 61%; p < 0.001). However, no information was
given about the impact of RT modality on outcome.
Surprisingly, the analysis of the impact of RT modality on
outcome showed that there was a significant relationship 
between institutional volume and survival only for patients
receiving 3D-CRT (5-year OS, 78.7% for HVI vs. 58.9% for
LVI; p < 0.001) and not for those receiving IMRT (5-year OS,
77.3% vs. 75.5%; p=0.170). In contrast, Boero et al. [14]
demonstrated a significant relationship between provider
volume and survival only for patients receiving IMRT and
not for those receiving conventional RT, including 2D- and
3D-CRT. The reason for this discrepancy is not clear but one
potential explanation might be that IMRT was first intro-
duced to Korea in 2001. Around this time, many guidelines
were published to help target delineation in head and neck
cancers. In addition, many educational sessions were pro-
vided by the Korean Society for Radiation Oncology to edu-
cate society members on how to contour targets and evaluate
treatment plans, which was not available for 3D-CRT. These
efforts may have had a standardizing effect on practice; thus,
no differences were found in outcome between HVI and LVI,
as a result of substantial improvement in LVI, approaching
that of HVI in the IMRT era. Notably, the 5-year OS rates 
improved from 58.9% with 3D-CRT to 75.5% with IMRT in
the LVI, whereas they were similar at 78.7% for 3D-CRT and
77.3% for IMRT in the HVI. Thus, the standardization of
practice by education might have a role for improvement of
outcome in LVI.
The experience of a radiation oncologist as indexed by
HCV might be one explanation for the survival advantage in
patient treated at a HVI, as shown here. RT is a primary treat-
ment for NPC, and a loco-regional control rate  90% can be
achieved with contemporary IMRT techniques [7,15]. How-
ever, NPC treatment is complex. Several confounding factors
influence the survival advantage in patients treated at a HVI.
The utilization of advanced imaging studies including MRI
and PET scans are helpful for accurate staging and target 
delineation for RT planning, which might improve treatment
outcome. In this study, MRI and PET were performed twice
more frequently at HVI than at LVI which might influence
the better outcome at HVI. In univariate analysis, the OS and
LRPFS were significantly associated with the utilization of
PET (yes vs. no) (5-year OS, 78.7% vs. 70.6%; p=0.012; 5-year
LRPFS, 82.0% vs. 74.5%; p=0.010, respectively), whereas they
were not associated with the utilization of MRI. In multivari-
ate analysis, the utilization of PET, however, became insignif-
icant. Concurrent chemotherapy is also crucial for locally-
advanced NPC based on its survival benefit, as shown in
multiple randomized-controlled trials and meta-analyses
[16,17]. Given the complexity of the treatment for NPC, a
multidisciplinary approach is recommended to improve long
term survival and decrease long term toxicity. A HVI is likely
to involve a multi-disciplinary team with more experienced
radiologists, medical oncologists, radiation oncologists, and
other supporting personnel, which might result in better out-
comes. Acute toxicities > grade 3 were more frequently 
reported in LVI and treatment related mortality was also
higher in LVI, which could have attributed to lower survival
outcome in LVI. However, their impact on survival outcome
could not be investigated because of the retrospective nature
of the study. 
Some limitations of our study should be mentioned. First,
the effect of non-RT factors was not fully controlled due to
the inherent shortcomings of a retrospective study. Detailed
information about the chemotherapy regimen, number of 
cycles, and use of neo-adjuvant vs. adjuvant chemotherapy
were not available in all patients. Nevertheless, most patients
were given CCRT (75%) and this proportion was well-bal-
anced between HVI and LVI. Given the lack of the informa-
tion about socioeconomic status, there was the possibility of
selection, in which patients with a higher socioeconomic sta-
tus and good overall health may have visited HVI and
sought expert opinions, which might have influenced the
outcome. 
The current study also had strengths. First, we included a
large cohort comprised only of patients with NPC. This 
homogeneity made it easier to specifically interpret the 
impact of HCV on NPC outcomes. Second, we used a data-
base for this retrospective study (KROG 11-06), which con-
tained data on all patients who met the inclusion criteria
(cT1-4N0-3M0, previously untreated NPC), thus including
nearly all patients treated at each institution. In contrast to a
national insurance database, these data included detailed 
information about the clinical status and treatment of each
patient.
Our results are unique because the HCV was more influ-
ential for patients receiving 3D-CRT than IMRT, which con-
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tradicts previous studies [13,14]. More importantly, our data
suggest that the difference in outcome between HVI and LVI
can be overcome potentially by the standardization of prac-
tice. 
A significant relationship was observed between HVI and
LVI for the clinical outcomes of patients with NPC. However,
the difference in outcome becomes insignificant in the IMRT
era, probably due to the standardization of practice by edu-
cation.
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